Cargando…

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine

INTRODUCTION: Lasmiditan is a selective serotonin (5-HT1F) receptor agonist approved in the US for the acute treatment ofmigraine in adults. This phase I, open-label, two-cohort study assessed the pharmacokinetics (PK), safety, and tolerability of lasmiditan in patients with migraine aged 6 to <...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Max, Nery, Emel Serap Monkul, Kerr, Lisa, Khanna, Rashna, Komori, Mika, Dennehy, Ellen B., Wilbraham, Darren, Winner, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195962/ https://www.ncbi.nlm.nih.gov/pubmed/33565026 http://dx.doi.org/10.1007/s40262-020-00966-z

Ejemplares similares

Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol
por: Tsai, Max, et al.
Publicado: (2020)

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
por: Blumenfeld, Andrew, et al.
Publicado: (2023)

Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls
por: Pearlman, Eric M., et al.
Publicado: (2020)

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022)

Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
por: Shapiro, Robert E., et al.
Publicado: (2019)

The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial
por: Takeshima, Takao, et al.
Publicado: (2022)

Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study
por: Wilbraham, Darren, et al.
Publicado: (2019)

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
por: Goadsby, Peter J, et al.
Publicado: (2019)

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Lasmiditan: A New Promising Drug in Migraine
por: Prakash, Sanjay, et al.
Publicado: (2021)

Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial
por: Matsumori, Yasuhiko, et al.
Publicado: (2022)

Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks
por: Tepper, Stewart J., et al.
Publicado: (2020)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
por: Brandes, Jan Lewis, et al.
Publicado: (2019)

Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
por: Rizzoli, Paul B
Publicado: (2014)

Budget impact of lasmiditan for the acute treatment of migraine in the United States
por: Milev, Sandra, et al.
Publicado: (2021)

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
por: Oswald, Jessica C, et al.
Publicado: (2018)

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
por: Kuca, Bernice, et al.
Publicado: (2018)

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
por: Anderson, Christopher C, et al.
Publicado: (2023)

Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
por: Kudrow, David, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects
por: Wilbraham, Darren, et al.
Publicado: (2020)

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies
por: Smith, Timothy, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease
por: Wilbraham, Darren, et al.
Publicado: (2021)

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
por: Lipton, Richard B., et al.
Publicado: (2020)

Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study
por: Ashina, Messoud, et al.
Publicado: (2021)

Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis
por: Basutkar, Roopa Satyanarayan, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
por: Szkutnik-Fiedler, Danuta
Publicado: (2020)

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
por: Tassorelli, C, et al.
Publicado: (2021)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials
por: Doty, Erin G., et al.
Publicado: (2022)

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
por: Krege, John H, et al.
Publicado: (2019)

Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis
por: Ahsan, Marya, et al.
Publicado: (2022)

The Effect and Safety of 5-HT(1F) Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis
por: Gu, Ping, et al.
Publicado: (2021)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2017)

Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
por: Doty, Erin Gautier, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n5cmqod6e0vl6l2c5tdehkkl6v